Best of ASCO - 2014 Annual Meeting

 

Welcome

Multiple Myeloma

Hematologic Malignancies—Plasma Cell Dyscrasia

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.

James R. Berenson

8005

A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.

Siyang Leng

8029

A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.

Orlando Bueno

TPS8061

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

Saad Zafar Usmani

8010

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

Maria-Victoria Mateos

8021

A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).

Sosana Delimpasi

TPS8056

A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Andrew Jenho Yee

8012

Adherence to pomalidomide in patients with multiple myeloma: A US-based claims study.

Justin Gatwood

e20008

An evaluation of c-myc aberrations in patients with newly diagnosed multiple myeloma (NDMM).

Amy Guzdar

e20006

Association of venous thromboembolism with increased mortality in patients with multiple myeloma.

Martin W. Schoen

8051

Autologous stem cell transplantation in multiple myeloma patients over age 75.

Ning Dong

8025

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

Noopur S. Raje

8007

Can bortezomib combined chemotherapy be helpful for even elderly unfit patients with newly diagnosed multiple myeloma.

Ho Sup Lee

e20020

Carfilzomib and cardiac events in a single institution non-Caucasian cohort.

Ankit Mangla

e20039

Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.

Robert Z. Orlowski

8032

Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

Valentine Richez

8017

Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.

Martin Gramatzki

8019

Characterization of resistance to APO010, a recombinant hexameric FAS ligand, in human myeloma cell lines.

Haatisha Jandu

e20025

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).

Sikander Ailawadhi

8050

Correlation between 24-hour urine protein and spot urine protein-to-creatinine ratio in multiple myeloma.

Saad Jamshed

e20042

Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma.

Eric Maiese

e20037

Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.

Jenny Willson

e20038

Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.

Ajai Chari

8002

Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

Michele Cavo

8031

Drivers of phase-based costs in patients with multiple myeloma.

Abdalla Aly

e20022

Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).

Surbhi Sidana

8045

Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.

Nikhil C. Munshi

8024

Economic burden of early progression in newly-diagnosed multiple myeloma patients.

Shivani Pandya

e20040

Effect of anticoagulation choice on survival for patients with myeloma being treated with a proteasome inhibitor.

Dianne Pulte

e20036

Effect of renal impairment (RI) on intravenous bisphosphonates (IVBP) and multiple myeloma (MM) treatment.

Debajyoti Bhowmik

e20007

Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.

James R. Berenson

e20012

Emerging immunotherapy and decade of early phase drug development: Systematic review of multiple myeloma treatment.

Warda Faridi

e20016

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial

8040

Factors associated with non-adherence to lenalidomide in patients with multiple myeloma.

Siyang Leng

e20031

FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.

Aviva C Krauss

8008

Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).

Joseph Mikhael

8038

Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016.

Andrew Cowan

e20023

Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).

Liana Nikolaenko

8028

Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial.

Katharine Gries

8042

Impact of adherence to pomalidomide on medication adherence in pre-existing chronic conditions in patients with multiple myeloma.

Justin Gatwood

e20010

Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

Michele Cavo

e20024

Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.

R Donald Harvey

8046

Impact of skeletal-related events on multiple myeloma treatment.

Debajyoti Bhowmik

e20009

Incidence and risks of pneumonia in patients with multiple myeloma treated with daratumumab: A systematic review and meta-analysis of randomized controlled trials.

Aung Tun

e20021

Lack of racial disparity in outcome of African American (AA) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (VA) hospitals.

Nathanael Fillmore

8033

Large retrospective study of lenalidome-dexamethasone (Rd) in patients older than 80 with multiple myeloma (MM): Is less more?

Magalie Pascale Tardy

e20035

Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions.

Yanshuo Cao

8039

Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304.

Sikander Ailawadhi

8015

Maintenance (MT) treatment (Tx) after lenalidomide, bortezomib, and dexamethasone (RVD) induction and stem cell transplant (SCT) in high-risk (HR) patients (pts) with newly diagnosed multiple myeloma (NDMM): A real-world analysis.

Rafael Fonseca

e20041

Molecular underpinnings of clinical disparity patterns in African American (AA) versus Caucasian American (CA) multiple myeloma (MM) patients.

Elizabeth M. Hill

8036

Natural history of delp53 multiple myeloma.

Arjun Lakshman

e20017

Novel treatment (Tx) use and associated outcomes among African American patients (pts) with multiple myeloma (MM): A SEER-Medicare analysis.

Kejal Parikh

e20030

Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

Maria-Victoria Mateos

8000

Outcome of multiple myeloma patients with renal failure: A retrospective study.

Ramavath Devendra Naik

e20026

Outcomes of spinal stabilization in multiple myeloma with unstable vertebral lesions background.

Tara Rajendran

e20028

Overall survival (OS) results of randomized phase III study (ADMYRE trial) of plitidepsin and dexamethasone (DXM) vs. DXM alone in patients with relapsed/refractory multiple myeloma (RRMM): Evaluation of the crossover impact.

Javier Gomez

8018

Oxidative processes in the blood during chemotherapy and lethality of patients with multiple myeloma.

Irina A. Goroshinskaya

e20027

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Luciano J. Costa

8004

Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).

Ajai Chari

8014

Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.

Nina Shah

8006

Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).

Thomas G. Martin

TPS8060

Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).

Robert Z. Orlowski

TPS8055

Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

David Samuel DiCapua Siegel

8027

Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.

Paul G. Richardson

8001

Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Pieter Sonneveld

TPS8059

Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.

Ben Buelow

8034

Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.

Cristina Gasparetto

8037

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.

Marcella Tschautscher

8030

Prospective evaluation of minimal residual disease in multiple myeloma following autologous stem cell transplantation(ASCT) and consolidation therapy.

Mukesh Patekar

e20033

Quality of life and cancer worry in a follow-up cohort of patients with asymptomatic monoclonal gammopathies.

Michelle Ann Theobald Hildebrandt

8049

Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

Saad Zafar Usmani

TPS8058

Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).

Jan Van Droogenbroeck

TPS8057

Real-world evidence of cardiac hospitalizations in carfilzomib- and non-carfilzomib-treated multiple myeloma patients in the United States.

Joseph Mikhael

8043

Real-world utilization of multiple myeloma treatments in the era of novel therapies: What is the current standard of care?

David Singer

e20019

Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.

Barry Paul

8047

Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.

Yarong Liu

8020

Risks of upper respiratory tract infection and pneumonia in patients with multiple myeloma receiving Daratumumab: A systematic review and meta-analysis of randomized controlled trials.

Katy Ticona

e20005

Self-reported adherence to lenalidomide as maintenance therpay for multiple myeloma after autologous stem cell transplantation.

Ilana Schlam

e20046

Single cell analysis of multiple myeloma.

Guy Ledergor

8026

Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).

Ajai Chari

8013

The MD Anderson modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (mCBAD) for the treatment of newly diagnosed (NDMM) and relapsed/refractory multiple myeloma (RRMM).

Samer Tabchi

8044

Time to deterioration (TTD) in health-related quality of life (HRQoL) with carfilzomib plus dexamethasone (Kd56) versus bortezomib plus dexamethasone (Vd) in the ENDEAVOR trial.

Katja Weisel

e20011

Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.

Sundar Jagannath

8041

Trends of hospitalization for multiple myeloma patients: Insights from the national inpatient sample database.

Anusha Vakiti

e20015

Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).

Francesca Maria Gay

8009

Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.

Mohammed A. Aljama

8023

Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.

Noa Biran

8022